Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer

Figure 2 Immunohistochemical validation of cyclin-dependent kinase inhibitor 2A and overall survival analysis. A: Immunohistochemical images showing cyclin-dependent kinase inhibitor 2A (CDKN2A) negativity in normal colon tissues and CDKN2A positivity in colorectal cancer (CRC) tissues; B: Comparison of CDKN2A expression in CRC and normal tissues based on the average option density (AOD). AOD calculated using ImageJ software; C: GEPIA shows gene overexpression of CDKN2A in both colon adenocarcinoma and rectum adenocarcinoma patients in comparison with normal people; D: The relationship between CDKN2A expression and overall survival in CRC patients. Patients with high CDKN2A expression have a poor prognosis, and those with low CDKN2A expression have a longer survival time. CRC: Colorectal cancer; AOD: Average option density; COAD: Colon adenocarcinoma; READ: Rectum adenocarcinoma; CDKN2A: Cyclin-dependent kinase inhibitor 2A.